Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Sep 19, 2019

Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

Sep 16, 2019

Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

Sep 10, 2019

Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

Sep 4, 2019

Cellectar Appoints Dov Elefant as Chief Financial Officer

Aug 15, 2019

CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

Aug 14, 2019

Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

Aug 12, 2019

Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

Jul 9, 2019

Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

May 21, 2019

Cellectar Biosciences Announces Closing of $10.0 Million Financing

May 20, 2019